News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GTX Corp Announces Presentation on the Ability of Capesaris® to Reduce Free Testosterone and Suppress PSA in Men With Castration Resistant Prostate Cancer



9/19/2012 8:49:19 AM

MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) announced today there will be a presentation on the mechanism of action of Capesaris® to induce sex hormone binding globulin (SHBG) and subsequently reduce free testosterone (FT) in men with castration resistant prostate cancer. On September 29, 2012, between 1:00 and 2:00pm Vienna time, at the European Society for Medical Oncology (ESMO) 2012 to be held in Vienna, Austria from September 28 through October 2, 2012, GTx will make a presentation entitled: “GTx-758, an Oral ERa Agonist, Increases Sex Hormone Binding Globulin, Reduces Free T and Decreases PSA in Patients With Castration Resistant Prostate Cancer.”

Read at BioSpace.com


comments powered by Disqus
GTX Corp
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES